Summary
Abbott Laboratories' 2015 10-K report reveals a company undergoing significant strategic shifts, including divestitures and acquisitions, aimed at strengthening its core healthcare businesses. The company reported net sales of $20.4 billion, with international markets accounting for approximately 70% of total sales. Key business segments include Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The year was marked by the sale of the developed markets branded generics pharmaceuticals business to Mylan and the acquisition of CFR Pharmaceuticals, bolstering its presence in emerging markets. Abbott also highlighted its ongoing investment in research and development, totaling $1.4 billion in 2015, across its diverse product portfolio. The company's financial health remains robust, with a strong cash flow and a commitment to returning value to shareholders through dividends and share repurchases. Looking ahead, Abbott announced its definitive agreement to acquire Alere Inc., a move expected to significantly enhance its diagnostics business.
Financial Highlights
55 data points| Revenue | $20.41B |
| Cost of Revenue | $8.75B |
| Gross Profit | $11.66B |
| SG&A Expenses | $6.79B |
| Operating Expenses | $17.54B |
| Operating Income | $2.87B |
| Interest Expense | $163.00M |
| Net Income | $4.42B |
| EPS (Basic) | $2.94 |
| EPS (Diluted) | $2.92 |
| Shares Outstanding (Basic) | 1.50B |
| Shares Outstanding (Diluted) | 1.51B |
Key Highlights
- 1Abbott Laboratories reported net sales of $20.4 billion for the fiscal year ended December 31, 2015.
- 2The company sold its developed markets branded generics pharmaceuticals business to Mylan Inc. in February 2015.
- 3Abbott completed the acquisition of CFR Pharmaceuticals S.A. in September 2014, strengthening its emerging markets presence.
- 4Research and development expenses were $1.4 billion in 2015, demonstrating continued investment in innovation.
- 5The company announced a definitive agreement to acquire Alere Inc., a leader in point-of-care diagnostics, for $5.8 billion.
- 6International sales constituted approximately 70% of Abbott's total net sales.
- 7Abbott continued to return value to shareholders, declaring dividends and repurchasing shares throughout the year.